Parsing the Options from Comparative Trials of Initial Antiretroviral Therapy
Forty-eight-week data presented at the 15th Retrovirus Conference demonstrated noninferiority for boosted atazanavir compared with lopinavir/r, abacavir/3TC compared with tenofovir/FTC, and once-daily compared with twice-daily lopinavir/r.
Welcome to Journal Watch. The content you requested requires sign in with a username and password.
Sign In
Sign Up
Print subscribers
Activate your free online account for full access to all site content and features.
Other visitors
Subscribe for full access to all site content and features. ($99/year)
Purchase a site pass for full access to all articles. ($19/7 days)
Or, simply register for free access to email alerts, site features, and article archives. (FREE)